Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2026 / 09:30 PM GMT

Release Date Price: €36.8 (+0.55%)

Transcript 10-K8-K

Key Points

Positve

Crinetics Pharmaceuticals Inc (CRNX) successfully launched its first commercial product, Palsonfi, for acromegaly, with growing uptake and positive feedback from prescribers and patients.
The company presented compelling phase 2 data for its second late-stage candidate, Atomelant, showing potential as a preferred treatment for congenital adrenal hyperplasia (CAH) and Cushing's disease.
Crinetics Pharmaceuticals Inc (CRNX) has a strong balance sheet with over $1 billion in cash equivalents and investments, providing financial stability and runway into 2030.
The company is making significant progress with payers, securing early formulary wins and reimbursement for Palsonfi, enhancing market access.
Crinetics Pharmaceuticals Inc (CRNX) is advancing a robust pipeline, including a new non-peptide drug conjugate program, CRM 9,682, targeting SST2 expressing tumors.

Negative

Research and development expenses remain high, with $85.1 million reported for the fourth quarter, reflecting ongoing clinical studies and commercialization efforts.
The company anticipates increased operating expenses in 2026, ranging between $600 and $650 million, due to continued investment in clinical trials and commercialization activities.
Despite the successful launch of Palsonfi, the company is still in the early stages of market penetration, with ongoing efforts needed to expand patient and prescriber engagement.
The transition from QuickStart programs to full reimbursement for Palsonfi is still evolving, with 50% of patients currently on QuickStart, indicating potential challenges in achieving full market access.
Crinetics Pharmaceuticals Inc (CRNX) faces uncertainties in clinical trial outcomes and regulatory approvals, which could impact future product launches and market expansion.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRNX.OQ - Crinetics Pharmaceuticals Inc
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call
Feb 26, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Kronnetics Pharmaceuticals, 4th quarter and full year 2025.

Financial results conference call.

At this time, all participants are in lonely mode following management's prepared remarks, we'll hold a question-and-answer session.

In order to ask a question, please press star, then one on your telephone.

3 tow, head of investor relations, please go ahead.

Thank you, operator.

Good afternoon, everyone, and thank you for joining us to discuss the 4th quarter and 4 year 2025 results.

Today on the call, we have Doctor Scott's brothers, founder and Chief Executive Officer, Doctor Alan Krasner, chief endocrinologist, and Toby Shoki, Chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.